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clorazepate (20mg 2× /d), and pregabalin (100 mg 3× /d). Because of 
resurgence of severe anxio-depressive symptoms, without any change 
of the treatment, the patient was readmitted 2 months later. Despite 
increasing the dose of clomipramine up to 225 mg/d, there was no 
clinical improvement, and the patient finally attempted to her life by 
abusing drugs. She then improved after 2 weeks on clomipramine 
IV (50 mg/d). Compliance was estimated good and no pharmacoki-
netic interactions with the rest of the treatment were found. C and 
DC plasma levels were measured, and CYP2D6/CYP2C19 genotype 
analyzed.
Results: The plasma levels of C and DC are given in the Table 
below. Measures were done at the steady state and at trough con-
centration for IV treatment and 10 hours after the last dose for oral 
treatment.
Clomipramine bioavailability, 50%.
The CYP2D6 genotyping was CYP2D6 *1/*2xN, compatible 
with an ultrarapid metabolizer. The CYP2C19 genotyping was 
CYP2C19*1/*1, compatible with an extensive metabolizer.
Conclusion: The lack of clinical effect of oral clomipramine after a 
dramatic response to IV administration and the low per os plasma 
levels of clomipramine and its active metabolite, desmethylclo-
mipramine, suggested a rapid phenotype for CYP2D6. This was 
confirmed by genotyping. This case stresses the value of genotype 
determination to assess treatment failures in a population of patient 
wherein lack of compliance is often mentioned.
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Introduction: Dravet syndrome (DS) is a rare pediatric epilepsy of 
early life onset characterized by pharmacoresistant hemi- or gen-
eralized (tonic)-clonic seizures and severe cognitive prognosis. The 
voltage-gated sodium channel SCN1A gene is mutated in 85% of 
the patients. Transgenic mice models of DS suggest that the mutation 
specifically involves GABAergic interneurons and leads to selective 
loss of sodium current affecting their firing properties. However, the 
mechanisms leading from interictal activity to seizure generation and 
the subtype of interneurons involved are not known. Computational 
modeling of neuronal network is currently used to analyze these mech-
anisms. The inconsistency of firing rate in GABAergic interneurons 
can be used as a starting point to build a computational model of DS.
Objectives: To find parameters and connections in the model that 
reproduce EEG patterns of DS patients.
Patients (or Materials) and Methods: We first made a quantitative 
and qualitative analysis of EEG recorded in DS patients during inter-
ictal, preictal, and ictal periods. We next used a lumped-parameter 
approach (mean-field model) lying at the level of neuronal popu-
lation and able to represent the generation of spontaneous EEG. 
This computational model includes 1 subpopulation of pyramidal 
cells and 2 subpopulations of interneurons (mediating fast and slow 
GABAergic currents).
Results: EEG signals were characterized by slow background 
activity (1–4 Hz), multifocal interictal epileptic spikes and, as far 
as hemi-clonic seizures were concerned, by fast oscillations at the 
onset of seizures. To mimic the effect of a SCN1A mutation, the fir-
ing rate of GABAergic current was modified in slow interneurons. 
Preliminary results show that appropriate alterations in the strengths 
of GABAergic and glutamatergic connections, and in the amplitudes 
of average EPSPs/IPSPs in the model successfully lead to slow back-
ground activity (1–4 Hz), generation of interictal epileptic spikes, 
and fast onset activity and seizure-like activity.
Conclusion: Our computational modeling of DS is therefore promis-
ing. Further optimization is needed for reproducing all the features 
of the real EEG from patients and identifying the key parameters of 
specific EEG patterns.
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Introduction: Several anticancer medicines evoke sensory adverse 
events, collectively referred to as chemotherapy-induced peripheral 
neuropathy (CIPN), which are represented by sensory symptoms. 
No effective therapy is currently available to treat or prevent CIPN, 
most likely because the underlying mechanisms are poorly under-
stood. A host of hypotheses has been proposed to explain CIPN, 
but nonetheless no unified mechanism that may reconcile results of 
clinical investigation and findings obtained in experimental animals 
has been advanced so far. Chemotherapeutic drugs, which produce 
CIPN, are known to increase oxidative stress and reactive oxygen, 
nitrogen, or carbonyl species (ROS, RNS, and RCS, respectively) 
and treatment with antioxidant substances has been shown to reduce 
sensory hypersensitivity in experimental animals and to exhibit some 
degree of protection in patients with CIPN. The transient potential 
receptor ankyrin 1 (TRPA1) is a nonselective cation channel, co-
expressed with TRP vanilloid 1 (TRPV1) in a subset of C-fiber noci-
ceptors, where it functions as a multimodal sensor to noxious stimuli. 
TRPA1 shows a unique sensitivity for an unprecedented number of 
endogenous reactive molecules produced at sites of tissue injury or 
inflammation, which include ROS, RNS and RCS. Bortezomib is 
a proteasome inhibitor used indifferent types of cancer. CIPN has 
Table. Doses and plasma levels.
Posology (mg/d)
Route of administration 150 50
oral intravenous
C (micromol/l) 0.3-0.8 0.17 0.28
DC (micromol/l) 0.14 0.27
C + DC (micromol/l) 0.8-1.6 0.31 0.55
